Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Phys Sportsmed ; : 1-6, 2023 Sep 22.
Article in English | MEDLINE | ID: mdl-37738218

ABSTRACT

OBJECTIVES: Track and field (T&F) is a highly popular sport for adolescents. The diversity of running, jumping, and throwing events within the sport can result in unique injury patterns for adolescent track and field participants. The purpose of this study was to estimate injury risk in adolescent T&F and describe the types of injuries resulting in ED visits, classified by T&F events. METHODS: Emergency department (ED) data from the National Electronic Injury Surveillance System were obtained for a 20-year period from 2000 through 2019. Cases involving 14- to 18-year-olds participating in T&F were classified by sex, case severity, involved body region, and the T&F event patients were engaged in at the time of their injury. National estimates and Injury rates were calculated using national high school T&F participation data. Longitudinal trends in ED visits were measured using linear regression. Rate ratios (RRs) were used to compare the risk and severity of ED visits by sex. RESULTS: 8,060 track and field related ED encounters were observed, representing an estimated 272,227 encounters nationally over the 20-year study period. The rate of ED encounters increased significantly over the study period (p < 0.001). Adolescent females exhibited a higher rate of ED encounters (RR: 1.23, 95% CI: 1.22-1.24), but a lower rate of hospital admissions (RR: 0.68, 95% CI: 0.64-0.73) compared to males. The lower extremity was the most commonly injured body region for most T&F events, but this differed for sprinting, high jumping, shot put, and javelin events. Most T&F events resulted in unique injury patterns characteristic of their athletic demands. CONCLUSIONS: There was an increasing trend of ED visits from adolescent T&F participants throughout the 20-year study period with different injury patterns observed by sex and T&F event discipline.

2.
PLoS Genet ; 13(10): e1007068, 2017 Oct.
Article in English | MEDLINE | ID: mdl-29084269

ABSTRACT

The coronary vasculature is an essential vessel network providing the blood supply to the heart. Disruptions in coronary blood flow contribute to cardiac disease, a major cause of premature death worldwide. The generation of treatments for cardiovascular disease will be aided by a deeper understanding of the developmental processes that underpin coronary vessel formation. From an ENU mutagenesis screen, we have isolated a mouse mutant displaying embryonic hydrocephalus and cardiac defects (EHC). Positional cloning and candidate gene analysis revealed that the EHC phenotype results from a point mutation in a splice donor site of the Myh10 gene, which encodes NMHC IIB. Complementation testing confirmed that the Myh10 mutation causes the EHC phenotype. Characterisation of the EHC cardiac defects revealed abnormalities in myocardial development, consistent with observations from previously generated NMHC IIB null mouse lines. Analysis of the EHC mutant hearts also identified defects in the formation of the coronary vasculature. We attribute the coronary vessel abnormalities to defective epicardial cell function, as the EHC epicardium displays an abnormal cell morphology, reduced capacity to undergo epithelial-mesenchymal transition (EMT), and impaired migration of epicardial-derived cells (EPDCs) into the myocardium. Our studies on the EHC mutant demonstrate a requirement for NMHC IIB in epicardial function and coronary vessel formation, highlighting the importance of this protein in cardiac development and ultimately, embryonic survival.


Subject(s)
Coronary Vessels/growth & development , Embryonic Development/genetics , Myosin Heavy Chains/genetics , Nonmuscle Myosin Type IIB/genetics , Pericardium/growth & development , Animals , Cell Differentiation/genetics , Coronary Vessels/metabolism , Embryo, Mammalian , Epithelial-Mesenchymal Transition/genetics , Humans , Hydrocephalus/genetics , Hydrocephalus/metabolism , Hydrocephalus/pathology , Mice , Mice, Knockout , Mutation , Myocardium/metabolism , Pericardium/metabolism
3.
Circ Res ; 121(9): 1058-1068, 2017 Oct 13.
Article in English | MEDLINE | ID: mdl-28821541

ABSTRACT

RATIONALE: Downregulation of the pacemaking ion channel, HCN4 (hyperpolarization-activated cyclic nucleotide gated channel 4), and the corresponding ionic current, If, underlies exercise training-induced sinus bradycardia in rodents. If this occurs in humans, it could explain the increased incidence of bradyarrhythmias in veteran athletes, and it will be important to understand the underlying processes. OBJECTIVE: To test the role of HCN4 in the training-induced bradycardia in human athletes and investigate the role of microRNAs (miRs) in the repression of HCN4. METHODS AND RESULTS: As in rodents, the intrinsic heart rate was significantly lower in human athletes than in nonathletes, and in all subjects, the rate-lowering effect of the HCN selective blocker, ivabradine, was significantly correlated with the intrinsic heart rate, consistent with HCN repression in athletes. Next-generation sequencing and quantitative real-time reverse transcription polymerase chain reaction showed remodeling of miRs in the sinus node of swim-trained mice. Computational predictions highlighted a prominent role for miR-423-5p. Interaction between miR-423-5p and HCN4 was confirmed by a dose-dependent reduction in HCN4 3'-untranslated region luciferase reporter activity on cotransfection with precursor miR-423-5p (abolished by mutation of predicted recognition elements). Knockdown of miR-423-5p with anti-miR-423-5p reversed training-induced bradycardia via rescue of HCN4 and If. Further experiments showed that in the sinus node of swim-trained mice, upregulation of miR-423-5p (intronic miR) and its host gene, NSRP1, is driven by an upregulation of the transcription factor Nkx2.5. CONCLUSIONS: HCN remodeling likely occurs in human athletes, as well as in rodent models. miR-423-5p contributes to training-induced bradycardia by targeting HCN4. This work presents the first evidence of miR control of HCN4 and heart rate. miR-423-5p could be a therapeutic target for pathological sinus node dysfunction in veteran athletes.


Subject(s)
Bradycardia/metabolism , Exercise/physiology , Gene Targeting/methods , Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels/metabolism , MicroRNAs/metabolism , Muscle Proteins/metabolism , Physical Conditioning, Animal/physiology , Potassium Channels/metabolism , Adolescent , Adult , Animals , Bradycardia/genetics , Bradycardia/physiopathology , Gene Knockdown Techniques/methods , Humans , Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels/genetics , Male , Mice , Mice, Inbred C57BL , MicroRNAs/genetics , Muscle Proteins/genetics , Physical Conditioning, Animal/methods , Potassium Channels/genetics , Sinoatrial Node/metabolism , Sinoatrial Node/physiopathology , Young Adult
4.
Stem Cell Res ; 20: 42-49, 2017 04.
Article in English | MEDLINE | ID: mdl-28257933

ABSTRACT

Adult fibroblasts can be reprogrammed into induced pluripotent stem cells (iPSC) for use in various applications. However, there are challenges in iPSC generation including low reprogramming efficiency, yield, cell survival and viability. Since the Hippo signalling pathway is a key pathway involved in regulating cell proliferation and survival, we here test whether modification of the Hippo pathway will enhance the efficiency of iPSC generation and improve their survival. The Hippo pathway was modified by genetic ablation of the mammalian sterile-20 like kinase 1 (Mst1), a major component of the pathway. Using adult skin fibroblasts isolated from Mst1 knockout mice (Mst1-/-) as a source of iPSC we found that genetic ablation of Mst1 leads to significantly increased reprogramming efficiency by 43.8%. Moreover, Mst1-/- iPSC displayed increase proliferation by 12% as well as an increase in cell viability by 20% when treated with a chemical hypoxic inducer. Mechanistically, we found higher activity of YAP, the main downstream effector of the Hippo pathway, in iPSC lacking Mst1. In conclusion, our data suggests that Mst1 can be targeted to improve the efficiency of adult somatic cell reprogramming as well as to enhance iPSC proliferation and survival.


Subject(s)
Cellular Reprogramming , Hepatocyte Growth Factor/genetics , Induced Pluripotent Stem Cells/cytology , Proto-Oncogene Proteins/genetics , Animals , Cell Line , Cell Proliferation , Cell Survival , Fibroblasts/cytology , Fibroblasts/metabolism , Hepatocyte Growth Factor/deficiency , Hippo Signaling Pathway , Induced Pluripotent Stem Cells/metabolism , Mice , Mice, Knockout , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/deficiency , Signal Transduction , Transcription Factors/genetics , Transcription Factors/metabolism
5.
J Biol Chem ; 289(35): 24275-88, 2014 Aug 29.
Article in English | MEDLINE | ID: mdl-25035424

ABSTRACT

The Hippo signaling pathway has recently moved to center stage in cardiac research because of its key role in cardiomyocyte proliferation and regeneration of the embryonic and newborn heart. However, its role in the adult heart is incompletely understood. We investigate here the role of mammalian Ste20-like kinase 2 (Mst2), one of the central regulators of this pathway. Mst2(-/-) mice showed no alteration in cardiomyocyte proliferation. However, Mst2(-/-) mice exhibited a significant reduction of hypertrophy and fibrosis in response to pressure overload. Consistently, overexpression of MST2 in neonatal rat cardiomyocytes significantly enhanced phenylephrine-induced cellular hypertrophy. Mechanistically, Mst2 positively modulated the prohypertrophic Raf1-ERK1/2 pathway. However, activation of the downstream effectors of the Hippo pathway (Yes-associated protein) was not affected by Mst2 ablation. An initial genetic study in mitral valve prolapse patients revealed an association between a polymorphism in the human MST2 gene and adverse cardiac remodeling. These results reveal a novel role of Mst2 in stress-dependent cardiac hypertrophy and remodeling in the adult mouse and likely human heart.


Subject(s)
Cardiomegaly/physiopathology , Protein Serine-Threonine Kinases/metabolism , Stress, Physiological , Animals , Apoptosis , Cardiomegaly/enzymology , Cardiomegaly/pathology , Cell Proliferation , Humans , In Situ Nick-End Labeling , MAP Kinase Signaling System , Male , Mice , Mice, Inbred C57BL , Phenylephrine/adverse effects , Proto-Oncogene Proteins c-raf/metabolism , Serine-Threonine Kinase 3
6.
Pharmacol Ther ; 142(2): 231-43, 2014 May.
Article in English | MEDLINE | ID: mdl-24333265

ABSTRACT

Patients with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) have a significantly increased risk of cardiovascular disease (CVD). The reason for this is unclear but may be due, at least in part, to the failure of endothelial repair mechanisms. Over the last 15 years there has been much interest in the mechanisms of endothelial renewal and its potential as a therapy for CVD. In the circulation there are two distinct populations of cells; myeloid angiogenic cells (MACs) which augment repair by the paracrine secretion of angiogenic factors, and outgrowth endothelial cells (OECs) which are true endothelial progenitor cells (EPCs) and promote vasculogenesis by differentiating into mature endothelium. There are marked abnormalities in the number and function of these cells in patients with RA and SLE. Inflammatory cytokines including interferon-alpha (IFNα) and tumour-necrosis factor alpha (TNFα) both impair MAC and OEC function ex vivo and may therefore contribute to the CVD risk in these patients. Whilst administration of mononuclear cells, MACs and other progenitors has improved cardiovascular outcomes in the acute setting, this is not a viable option in chronic disease. The pharmacological manipulation of MAC/OEC function in vivo however has the potential to significantly improve endothelial repair and thus reduce CVD in this high risk population.


Subject(s)
Arthritis, Rheumatoid/therapy , Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/therapy , Endothelial Cells , Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/therapy , Stem Cell Transplantation , Stem Cells , Angiogenic Proteins/blood , Animals , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/diagnosis , Cardiovascular Diseases/blood , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/etiology , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Endothelial Cells/pathology , Endothelial Cells/transplantation , Humans , Inflammation Mediators/blood , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Regeneration , Stem Cells/drug effects , Stem Cells/metabolism , Stem Cells/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...